CINGULATE INC shares face pressure after the United States Food and Drug Administration (FDA) declined to approve its ADHD treatment, CTx-1301, on Tuesday afternoon. The regulator cited manufacturing-related concerns rather than issues with the drug's safety or clinical effectiveness. This delay forces the developer to burn through cash reserves as it navigates a crowded market of established competitors.

Manufacturing Hurdles Delay Market Entry